Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15219086 | 1.00 | TDP1 (0.40) | TDP1SMN1; SMN2LMNACRBNMMP2 | |
| SCHEMBL15014724 | 0.88 | TDP1 (0.42) | TDP1SMN1; SMN2LMNACRBNMMP2 | |
| SCHEMBL15219011 | 0.88 | TDP1 (0.42) | TDP1SMN1; SMN2LMNACRBNMMP2 | |
| SCHEMBL14048429 | 0.78 | TDP1 (0.39) | TDP1LMNACRBNMMP2MMP3 | |
| SCHEMBL15216893 | 0.75 | LMNA (0.37) | TDP1LMNACRBN | |
| SCHEMBL12328897 | 0.73 | TDP1 (0.45) | TDP1LMNACRBN | |
| SCHEMBL9813587 | 0.70 | SMN1; SMN2 (0.44) | TDP1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL18133096 | 0.70 | PYGM (0.45) | TDP1CRBN | |
| SCHEMBL10215944 | 0.70 | SMN1; SMN2 (0.47) | TDP1SMN1; SMN2CRBNALDH1A1USP2 | |
| SCHEMBL15216897 | 0.70 | PYGM (0.45) | TDP1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907128-B2 | Boron compound with amino acid skeleton containing cyclo ring-type ring | STELLA PHARMA CORPORATION (JP) | 2014-12-09 | — | — | US | disclosed |
| US-20130225861-A1 | Boron Compound With Amino Acid Skeleton Containing Cyclo Ring | STELLA PHARMA CORPORATION (JP) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225861-A1 | Boron Compound With Amino Acid Skeleton Containing Cyclo Ring | BCAT1, BCAT2, SLC1A5 | TDP1 3968/4885SMN1; SMN2 1642/4885LMNA 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.